✦ LIBER ✦

Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg

✍ Scribed by Zhe Shi; Yusuke Okuno; Muhaimin Rifa'i; Agustina Tri Endharti; Kazuyuki Akane; Ken-ichi Isobe; Haruhiko Suzuki

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 932 KB
Volume: 39
Category: Article
ISSN: 0014-2980
DOI: 10.1002/eji.200939314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of the immunoregulatory

Characterization of the immunoregulatory function of human TCR-αβ+ CD4−CD8− double-negative T cells

✍ Simon Voelkl; Regina Gary; Andreas Mackensen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

Acquisition of regulatory function by hu

Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF

✍ Vitaly Ablamunits; Brygida Bisikirska; Kevan C. Herold 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 530 KB

Differential roles for CXCR3 in CD4+ and

Differential roles for CXCR3 in CD4+ and CD8+ T cell trafficking following viral infection of the CNS

✍ Linda N. Stiles; Martin P. Hosking; Robert A. Edwards; Robert M. Strieter; Thoma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 323 KB 👁 1 views

CTLA-4 co-receptor impacts on the functi

CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets

✍ Christopher E. Rudd 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

The co-expression of 2B4 (CD244) and CD1

The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function

✍ Jérôme Rey; Jérôme Giustiniani; Francoise Mallet; Valèrie Schiavon; Laurence Bou 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

NKG2A is a marker for acquisition of reg

NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody

✍ Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

## Abstract Treatment with anti‐CD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, anti‐CD3 mAb does not induce Tregs in vitro.